Paraneoplastic syndrome: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 18: Line 18:
**[[Pyoderma gangrenosum]]
**[[Pyoderma gangrenosum]]


*Neurological paraneoplastic syndromes <ref>{{MeshName|Nervous+system+paraneoplastic+syndromes}}</ref>
*Neurological paraneoplastic syndromes <ref>{{MeshName|Nervous+system+paraneoplastic+syndromes}}</ref><ref name="pmid19620862">{{cite journal |vauthors=Didelot A, Honnorat J |title=Update on paraneoplastic neurological syndromes |journal=Curr Opin Oncol |volume=21 |issue=6 |pages=566–72 |date=November 2009 |pmid=19620862 |doi=10.1097/CCO.0b013e3283306647 |url=}}</ref>
**[[Paraneoplastic cerebellar degeneration]] associated with lung, ovarian, breast, lymphatic, and other cancers
**[[Paraneoplastic cerebellar degeneration]] associated with lung, ovarian, breast, lymphatic, and other cancers
**[[Encephalomyelitis]] (inflammation of the brain and spinal cord)
**[[Encephalomyelitis]] (inflammation of the brain and spinal cord)
Line 27: Line 27:
**[[Polymyositis]]
**[[Polymyositis]]
**[[Lambert-Eaton myasthenic syndrome]] (LEMS) in small-cell [[lung cancer]]
**[[Lambert-Eaton myasthenic syndrome]] (LEMS) in small-cell [[lung cancer]]
**Myasthenia gravis
**Subacute (peripheral) sensory neuropathy
**Autonomic neuropathy


*Hematological paraneoplastic syndromes <ref name="pmid9208888">{{cite journal |author=Staszewski H |title=Hematological paraneoplastic syndromes |journal=Semin. Oncol. |volume=24 |issue=3 |pages=329–33 |year=1997 |pmid=9208888 |doi=}}</ref>
*Hematological paraneoplastic syndromes <ref name="pmid9208888">{{cite journal |author=Staszewski H |title=Hematological paraneoplastic syndromes |journal=Semin. Oncol. |volume=24 |issue=3 |pages=329–33 |year=1997 |pmid=9208888 |doi=}}</ref>

Revision as of 16:51, 5 June 2019

Paraneoplastic syndrome Microchapters

Patient Information

Overview

Classification

Endocrine
Musculocutaneous
Neurological
Hematological
Others

Causes

Differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Gertrude Djouka, M.D.[2]

Synonyms and keywords: Paraneoplastic syndrome

Overview

A paraneoplastic syndrome is a disease or symptom that is the consequence of the presence of cancer in the body, but is not due to the local presence of cancer cells. These phenomena are mediated by humoral factors (by hormones or cytokines) excreted by tumor cells or by an immune response against the tumor. Sometimes the symptoms of paraneoplastic syndromes show even before the diagnosis of a malignancy.

Classification

Paraneoplastic syndromes can be divided into 4 main categories:

Causes

Differential diagnosis

References

  1. Cohen PR, Kurzrock R (1997). "Mucocutaneous paraneoplastic syndromes". Semin. Oncol. 24 (3): 334–59. PMID 9208889.
  2. Nervous+system+paraneoplastic+syndromes at the US National Library of Medicine Medical Subject Headings (MeSH)
  3. Didelot A, Honnorat J (November 2009). "Update on paraneoplastic neurological syndromes". Curr Opin Oncol. 21 (6): 566–72. doi:10.1097/CCO.0b013e3283306647. PMID 19620862.
  4. Dalmau J, Tüzün E, Wu HY; et al. (2007). "Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma". Ann. Neurol. 61 (1): 25–36. doi:10.1002/ana.21050. PMC 2430743. PMID 17262855. Unknown parameter |month= ignored (help)
  5. Staszewski H (1997). "Hematological paraneoplastic syndromes". Semin. Oncol. 24 (3): 329–33. PMID 9208888.
  6. Paraneoplastic+endocrine+syndromes at the US National Library of Medicine Medical Subject Headings (MeSH)
  7. Stewart AF (January 2005). "Clinical practice. Hypercalcemia associated with cancer". N. Engl. J. Med. 352 (4): 373–9. doi:10.1056/NEJMcp042806. PMID 15673803.
  8. Spinazzé S, Schrijvers D (April 2006). "Metabolic emergencies". Crit. Rev. Oncol. Hematol. 58 (1): 79–89. doi:10.1016/j.critrevonc.2005.04.004. PMID 16337807.
  9. Raftopoulos H (December 2007). "Diagnosis and management of hyponatremia in cancer patients". Support Care Cancer. 15 (12): 1341–7. doi:10.1007/s00520-007-0309-9. PMID 17701059.
  10. Ellison DH, Berl T (May 2007). "Clinical practice. The syndrome of inappropriate antidiuresis". N. Engl. J. Med. 356 (20): 2064–72. doi:10.1056/NEJMcp066837. PMID 17507705.
  11. Teale JD, Marks V (October 1998). "Glucocorticoid therapy suppresses abnormal secretion of big IGF-II by non-islet cell tumours inducing hypoglycaemia (NICTH)". Clin. Endocrinol. (Oxf). 49 (4): 491–8. PMID 9876347.